Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3’s ability to drive the adaptive and innate immune systems against cancer. IMP761 is an immunosuppressive agonist antibody to LAG-3, which has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells. Its third product candidate is LAG525, an antagonist (blocking) antibody targeting the LAG-3 molecule on T cells with potential applications in the treatment of cancer. Its fourth product candidate is IMP731 (GSK 781), a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity.
Símbolo de cotizaciónIMMP
Nombre de la empresaImmutep Ltd
Fecha de salida a bolsaJun 23, 1988
Director ejecutivoMr. Marc Voigt
Número de empleados- -
Tipo de seguridadDepository Receipt
Fin del año fiscalJun 23
DirecciónLevel 32, Suite 32.07 Australia Square
CiudadSYDNEY
Bolsa de valoresNASDAQ Global Market Consolidated
PaísAustralia
Código postal2000
Teléfono61283157003
Sitio Webhttps://www.immutep.com/
Símbolo de cotizaciónIMMP
Fecha de salida a bolsaJun 23, 1988
Director ejecutivoMr. Marc Voigt
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos